Autolus Therapeutics plc (NASDAQ:AUTL) Receives Positive Consensus Rating from Analysts

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) have received an average recommendation of "Buy" from the six research firms currently analyzing the stock, as reported by Marketbeat Ratings. All six analysts have assigned a buy rating to the stock, with the average price target for the next year set at $9.52.

A number of equity research analysts have recently published reports regarding Autolus shares. For instance, Wells Fargo & Company lowered their target price for Autolus Therapeutics from $8.00 to $6.00, while maintaining an "overweight" rating in their research report released on Friday. Meanwhile, Needham & Company LLC reiterated a "buy" rating and set a target price of $10.00 for the company in a report dated January 13th.

Investor Activity and Hedge Fund Interest

Several institutional investors have recently adjusted their stakes in Autolus Therapeutics. For example, Wellington Management Group LLP increased its ownership by 4.6% in the fourth quarter, resulting in a total of 25,345,680 shares valued at $59,562,000 after acquiring an additional 1,125,454 shares. Additionally, FMR LLC raised its holdings in Autolus Therapeutics by 44.6% during the third quarter to own 17,773,873 shares, reflecting a value of $64,519,000 after purchasing an extra 5,478,706 shares in the last quarter. Another investor, TFG Asset Management GP Ltd, increased its ownership by 3.1%, holding 8,250,000 shares worth about $19,388,000 after buying 250,000 additional shares. Furthermore, Candriam S.C.A. entered a new position in Autolus Therapeutics valued at approximately $7,500,000 during the same quarter. Lastly, AXA S.A. also acquired shares in Autolus worth about $4,288,000. Overall, institutional investors now hold 72.83% of the company’s stock.

Stock Performance Overview

On the NASDAQ, AUTL experienced a slight increase of $0.03 on Friday, bringing its price to $1.70. A total of 1,642,224 shares were traded, surpassing the average trading volume of 1,375,171 shares. The stock has seen a 1-year low of $1.57 and a 1-year high of $6.60, with a 50-day moving average of $2.03 and a 200-day moving average of $2.93. Currently, the company has a market capitalization of $452.36 million, a price-to-earnings ratio of -1.40, and a beta of 2.07.

Autolus Therapeutics last reported its quarterly earnings results on March 20th, announcing an earnings per share figure of ($0.09), beating analysts' expectations, which forecasted ($0.21) by $0.12. The company reported $0.03 million in revenue for the quarter, significantly lower than the estimated $2.98 million. Analysts predict that Autolus Therapeutics will end up posting an EPS of -0.94 for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing T cell therapies aimed at treating cancer and autoimmune diseases. Their clinical-stage programs feature several investigational therapies, including obecabtagene autoleucel (AUTO1), targeting CD19 and currently in Phase 1b/2 trials for adults with ALL; AUTO1/22, a therapy being tested in pediatric patients with relapsed or refractory ALL; AUTO4, aimed at treating peripheral T-cell lymphoma; AUTO6NG, an investigational therapy targeting GD2 for neuroblastoma; and AUTO8, which is in development for multiple myeloma.

Conclusion

This news underscores the positive outlook from analysts and reflects the growing interest from institutional investors, making Autolus Therapeutics an interesting option for potential investors looking at biotech companies. Despite the recent stock performance and earnings report, the overall sentiment remains optimistic in the market.

Autolus, Therapeutics, Stocks